Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies (2021)
Attributed to:
Overcoming Ibrutinib and Venetoclax resistance in Chronic Lymphocytic Leukaemia.
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s41375-021-01322-1
PubMed Identifier: 34148055
Publication URI: http://europepmc.org/abstract/MED/34148055
Type: Journal Article/Review
Parent Publication: Leukemia
Issue: 1
ISSN: 0887-6924